drugset / Trial / NCT00003181

Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer

NCT00003181

Phase 2 Unknown 35 enrolled Hope Cancer Institute, Inc.
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining chemotherapy with interleukin-2 and GM-CSF may be a more effective treatment for kidney cancer. PURPOSE: Phase II trial to study the effectiveness of low-dose interleukin-2, vinblastine, and GM-CSF in treating patients with metastatic kidney cancer.

Timeline

Start
1997-05
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Vinblastine Small molecule Intravenous
Subject aldesleukin Protein / enzyme biologic Subcutaneous
Subject sargramostim Protein / enzyme biologic Subcutaneous

Indications